Trials / Completed
CompletedNCT00166543
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 146 (actual)
- Sponsor
- SRI International · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
Detailed description
The objective of this study is to investigate the efficacy and safety of TAS-108 administered in postmenopausal patients with locally advanced or locally recurrent inoperable or progressive metastatic breast carcinoma who have previously responded to one or two standard endocrine therapies, with or without one prior chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS-108 |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2005-09-14
- Last updated
- 2015-08-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00166543. Inclusion in this directory is not an endorsement.